KLOW common uses, half-life, side effects and more

KLOW is a four-peptide gray-market blend of GHK-Cu, BPC-157, TB-500, and KPV. It is the GLOW blend with KPV added for an anti-inflammatory angle in the gut and skin. People use it for skin and cosmetic recovery, soft-tissue and post-procedure recovery, and inflammatory gut or skin symptoms. It is sold as a single premixed injectable vial. No regulator has approved it. The cosmetic status of topical Copper Tripeptide-1 does not cover injected KLOW. BPC-157 and TB-500 are banned in tested sport.

• Skin quality, texture, and cosmetic recovery
• Post-procedure and post-surgical recovery under clinic protocols
• Tendon, ligament, muscle, and joint recovery
• Wound and scar healing support
• Inflammatory gut or skin symptoms that the added KPV targets

Five days a week or daily during the first weeks

Common KLOW protocols inject roughly 2 to 4 mg of total blend under the skin five days a week or daily to start. Reported practice spreads more widely from about 0.5 to 6 mg per injection. GHK-Cu makes up about 62 percent of the 80 mg vial and drives any total-milligram figure. The usual vial holds 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. A 2 to 4 mg dose delivers 1.25 to 2.5 mg GHK-Cu plus 250 to 500 mcg each of BPC-157, TB-500, and KPV. That GHK-Cu amount spans the usual 1 to 2 mg injected range and can top it. The BPC-157 amount matches its usual 250 to 500 mcg daily range. Delivered TB-500 sits below its standalone per-dose amount. The frequent schedule partly offsets that. Delivered KPV lands at or below the low end of injected KPV practice.

• Every 1 mg of total blend from the 80 mg vial delivers 625 mcg GHK-Cu plus 125 mcg each of BPC-157, TB-500, and KPV
• Separate vials let each peptide run on its own schedule because the fixed blend moves all four together
• Clinic cycles commonly run several weeks on before a few weeks off
• A vial labeled TB-500 may hold either the short Ac-LKKTETQ fragment or the different full-length thymosin beta-4 protein
• A GLOW vial is this blend without KPV and should not be logged as four-component KLOW
• Some sellers reuse the KLOW name for a two-peptide KPV and BPC-157 product so the label should list all four peptides

No combination pharmacokinetic study of KLOW exists. Its components clear at different rates. BPC-157 has an animal plasma half-life under 30 minutes. Full-length thymosin beta-4 clears with a plasma half-life near 0.5 to 2 hours after an intravenous dose. The TB-500 fragment itself has never been measured in people. GHK-Cu has no human pharmacokinetic data by any route. KPV has no pharmacokinetic study in any species.

KLOW solution is blue to blue-violet from the GHK-Cu copper complex. Loss of that color can signal GHK-Cu degradation. Protect the powder and solution from light, heat, oxidizers, chelators such as EDTA, and repeated freeze-thaw cycles. No label-backed storage window exists for the injectable blend.

• Injection-site redness, itching, bruising, swelling, soreness, or blue copper staining
• Injection pain from the GHK-Cu component that often begins hours after the shot
• Headache, nausea, dizziness, fatigue, or lightheadedness reported by peptide users
• Metallic taste or gastrointestinal upset at higher injected GHK-Cu exposure
• Tiredness, mental fog, or a brief flu-like feeling reported by TB-500 users

• GHK-Cu

  1.25 to 2.5 mg per 2 to 4 mg blend injection from the 80 mg vial

• BPC-157

  250 to 500 mcg per 2 to 4 mg blend injection from the 80 mg vial

• TB-500

  250 to 500 mcg per 2 to 4 mg blend injection from the 80 mg vial

• KPV

  250 to 500 mcg per 2 to 4 mg blend injection from the 80 mg vial

KLOW combines four separate repair and inflammation signals in one injection. GHK-Cu is a copper-carrying tripeptide tied in skin and wound models to fibroblast activity, matrix turnover, and the copper-dependent enzymes that cross-link collagen. BPC-157 has no confirmed human receptor. Animal work reports raised VEGFR2 signaling without raised VEGF-A, nitric oxide effects, and better blood flow to injured tissue. TB-500 is the acetylated LKKTETQ fragment of thymosin beta-4. That fragment binds actin and drives cell migration and new vessel growth in laboratory models. The full protein's anti-inflammatory and cell-survival actions sit in regions the fragment lacks. KPV enters gut and immune cells through the PepT1 transporter and lowers NF-kB inflammatory signaling. No study shows the combination outperforms its separate components.

Direct evidence for KLOW as a finished blend is very low. No controlled human trial, case series, animal study, or pharmacokinetic study of the four peptides together was found. The ratio and dose come from market products and community protocols rather than dose-finding research. Topical GHK-Cu has small human skin and wound studies. Injected GHK-Cu has no published human use at all. BPC-157 rests mostly on animal and cell work from a small number of groups. TB-500 evidence is weaker than the full-length thymosin beta-4 data it borrows from. No human study has given the TB-500 fragment itself for healing. KPV has replicated gut anti-inflammatory work in cells and mice but still lacks any human exposure data.

• BPC-157 and TB-500 are banned in tested sport so treat KLOW as prohibited at all times
• The injectable blend has no regulatory approval and carries FDA safety flags for limited human data and immunogenicity risk
• Injected GHK-Cu delivers copper straight past the gut and raises risk for people with Wilson disease, copper overload, liver disease, or copper allergy
• People with active or recent cancer, unexplained masses, or proliferative retinopathy should avoid it because the cell-migration and repair biology is untested in those settings
• Blood thinners, bleeding or clotting disorders, and planned surgery need clinician review because the peptides' effect on human clotting is unstudied
• Pregnancy, breastfeeding, pediatric use, and research-chemical identity or sterility failures have no adequate safety data